Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 2, 2000

View Archived Issues

InSite Vision licenses novel TIGR modifier gene

Nexell acquires access to Diaclone antibodies for use in cell therapy

Patent applications filed by IGT for neuropharmaceuticals

Inhale Therapeutic Systems makes considerable progress in 1999

Allergan highlights Q4 1999 progress

Promising Sepracor compound with triple mechanism of action enters clinical testing

Cel-Sci receives MIPS award to support TB vaccine development

Phase II testing of third-generation ultrasound contrast agent commences at Acusphere

Ares-Serono licenses rhLIF from Amrad for infertility indication

Brief application of PEG reverses damage from spinal cord injury in guinea pigs

Are cannabinoid receptors involved in the IOP-lowering effects of cannabinoids?

Monsanto and Pharmacia & Upjohn file preliminary joint proxy statement with SEC

1F7 antibody inhibits destruction of CD4+ cells

Diabetes vaccine from Diamyd completes phase I testing

Patient enrollment completed in phase II trial of memantine for AIDS-related dementia

Patient enrollment begins in U.S. phase III trial of beraprost

NDA filed for once-daily didanosine capsules

Diacyl hydrazine compounds from SB target cathepsin K

Isis compounds modulate expression of antiapoptotic proteins A1 and mcl-1

More substituted carbapenems designed at Merck for infections due to resistant pathogens

Improved anticancer anthracene derivatives designed at BTG

Visudyne market introduction announced

Piperidine, pyrrolidine and pyrroline derivatives selectively affect 5-HT function

Contrast agents for radiological use in development at Guerbet

Synthesis of TA-949, an orally active 1-beta-methylcarbapenem

Apoptotic and antibacterial cyclohexapeptide fungal metabolite discovered in Japan

Edex/Viridal preferred, more efficacious than other ED therapies

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 11, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for June 12, 2025.
Deep Apple signs big Novo deal for cardiometabolic small molecules
BioWorld
Deep Apple Therapeutics Inc. could bring in as much as $812 million in a new collaboration and license deal with Novo Nordisk A/S. The total includes an...
23andme genetic privacy concerns garner Congressional scrutiny
BioWorld MedTech
The bankruptcy of genetic testing service 23andme Holding Corp. prompted a reaction from many quarters, but a June 11 Senate hearing highlighted an interest in...
3Sbio revs on with phase II data in tight PD-1/VEGF bispecific race
BioWorld
3Sbio Inc. reported interim phase II study results of its PD-1/VEGF bispecific antibody, SSGJ-707 – a “fabulous” asset, according to Pfizer Inc. CEO Albert...